The board of directors of the company resolved to request the shareholders to authorize the board of directors to handle cash-increase of common shares to issue overseas depository receipts

  1. Date of the board of directors resolution: May 11, 2018
  2. Source of capital increase funds: ash-increase of common shares to issue overseas depository receipts
  3. Number of shares issued: no more than 15,000,000 shares
  4. Par value per share: NT$10
  5. Total monetary amount of the issue: To be determined
  6. Issue price: To be determined
  7. Number of shares subscribed by or allotted to employees: To be determined
  8. Number of shares publicly sold: To be determined
  9. Ratio of shares subscribed by or allotted as stock dividends to existing shareholders: To be determined
  10. Method of handling fractional shares and shares unsubscribed by the deadline: To be determined
  11. Rights and obligations of the newly issued shares: same as existing common shares
  12. Utilization of the funds from the capital increase: enrich working capital to support new drug research and development
  13. Any other matters that need to be specified: the case will be raised in the 2018 Annual General Meeting